Therapy patterns were examined across various subgroups during the first 6-months of this 3 year prospective longitudinal study (LANDMARC; CTRI/2017/05/008452). During the observational period investigators were free to modify treatment in adults with T2D controlled/uncontrolled on ≥2 antihyperglycemic medications. Treatment patterns were analyzed using descriptive statistics and paired t-test. From baseline to 6-months (visit 2 [V2]), glycemic parameters analyzed for 5703 subjects improved significantly (p<0.001) across all treatment types (Table). This improvement was more evident in the insulin subgroup vs. insulin naïve subgroup (p<0.0001). No difference (p=0.7746) in mean A1C values of those receiving >3 OADs vs. ≤3 OADs was noted in insulin naïve subgroup. Notably, in participants receiving insulin along with OADs, PPG improved more in basal vs. premix regimen (p=0.0024). Overall, insulin regimen was more effective than OADs. Intensification of treatment with >3 OADs may not be effective in improving glycemic parameters. In real-world setting, adding basal insulin may be more effective than premix.
R. Ghosh: Employee; Self; Sanofi. A.K. Das: Advisory Panel; Self; Novo Nordisk A/S, Sanofi. A. Mithal: Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Johnson & Johnson, Lilly Diabetes, Novo Nordisk A/S. S. Joshi: Advisory Panel; Self; Novo Nordisk A/S, Roche Pharma, Sanofi. K. Kumar: None. S. Kalra: Advisory Panel; Self; Eli Lilly and Company. Speaker’s Bureau; Self; Novo Nordisk A/S, Sanofi-Aventis. A. Unnikrishnan: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. Speaker’s Bureau; Self; Eli Lilly and Company, Ipca Laboratories, Merck Sharp & Dohme Corp., Novartis AG. H. Thacker: None. B. Sethi: None. S. Mohanasundaram: Employee; Self; Sanofi. S.K. Menon: None. A. Nair: Employee; Self; Sanofi. N. Rais: None. S. Wangnoo: None. S. Chowdhury: Advisory Panel; Self; Novo Nordisk A/S. A.H. Zargar: None.
Sanofi India Limited
